NASDAQ:CLSD Clearside Biomedical (CLSD) Stock Price, News & Analysis $1.17 +0.04 (+3.54%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.12▼$1.1850-Day Range$1.08▼$1.4952-Week Range$0.65▼$2.12Volume296,235 shsAverage Volume265,288 shsMarket Capitalization$87.43 millionP/E RatioN/ADividend YieldN/APrice Target$4.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Clearside Biomedical alerts: Email Address Clearside Biomedical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside293.2% Upside$4.60 Price TargetShort InterestHealthy0.16% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 9 Articles This WeekInsider TradingAcquiring Shares$35,145 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.63) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector353rd out of 936 stocksPharmaceutical Preparations Industry165th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearside Biomedical has only been the subject of 3 research reports in the past 90 days.Read more about Clearside Biomedical's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.16% of the outstanding shares of Clearside Biomedical have been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently decreased by 48.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLSD. Previous Next 3.1 News and Social Media Coverage News SentimentClearside Biomedical has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Clearside Biomedical this week, compared to 2 articles on an average week.Search Interest12 people have searched for CLSD on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows7 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,145.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.20% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 18.75% of the stock of Clearside Biomedical is held by institutions.Read more about Clearside Biomedical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clearside Biomedical are expected to grow in the coming year, from ($0.63) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Clearside Biomedical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” Please, watch this now before it’s too late. About Clearside Biomedical Stock (NASDAQ:CLSD)Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Read More CLSD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLSD Stock News HeadlinesJuly 25 at 4:09 PM | seekingalpha.comClearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)July 25 at 8:28 AM | americanbankingnews.comNeedham & Company LLC Reaffirms Buy Rating for Clearside Biomedical (NASDAQ:CLSD)July 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...July 23 at 1:07 AM | americanbankingnews.comClearside Biomedical, Inc. (NASDAQ:CLSD) Receives $4.60 Consensus Price Target from AnalystsJuly 22, 2024 | globenewswire.comClearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ETJuly 11, 2024 | globenewswire.comClearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory BoardJune 27, 2024 | globenewswire.comClearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug DeliveryJune 25, 2024 | benzinga.comWhy Is Clearside Biomedical Stock Gaining Today?July 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...June 12, 2024 | globenewswire.comClearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit MeetingMay 22, 2024 | investing.comClearside Biomedical Inc (CLSD)May 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: Clearside Biomedical’s Drug Delivery System Endorsed by RETINA and Poised for Market GrowthMay 21, 2024 | globenewswire.comClearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®May 13, 2024 | markets.businessinsider.comBuy Rating for Clearside Biomedical Amid Promising CLS-AX Trial Progress and Sufficient Cash RunwayMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Clearside Biomedical’s Promising Phase 2b Odyssey Trial and Strategic CMO Hire Signal Strong OutlookMay 10, 2024 | finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Clearside Biomedical Inc Earnings CallMay 10, 2024 | markets.businessinsider.comBuy Rating on Clearside Biomedical: Anticipating ODYSSEY Trial Success and Market Growth PotentialSee More Headlines Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CLSD CUSIPN/A CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$4.60 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+303.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,490,000.00 Net Margins-413.73% Pretax Margin-413.73% Return on EquityN/A Return on Assets-94.66% Debt Debt-to-Equity RatioN/A Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual Sales$8.23 million Price / Sales10.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-4.56Miscellaneous Outstanding Shares74,730,000Free Float67,856,000Market Cap$85.19 million OptionableOptionable Beta2.43 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. George M. Lasezkay J.D. (Age 72)Pharm.D., Pharma.D., President, CEO & Director Comp: $836.15kMr. Charles A. Deignan (Age 60)Chief Financial Officer Comp: $568.68kDr. Thomas A. Ciulla M.B.A. (Age 59)M.D., Chairman of Scientific Advisory Board Comp: $531.52kMs. Jenny R. Kobin (Age 57)Head of Investor Relations Mr. Rick McElhenySenior Vice President of Corporate Development & Alliance ManagementMr. Rafael V. Andino (Age 59)Senior Vice President of Engineering & Manufacturing Ms. Susan L. Coultas Ph.D.Chief Clinical OfficerDr. Ngai Hang Chong FRCOphthM.D., Chief Medical OfficerMr. Leslie B. Zacks (Age 55)Secretary More ExecutivesKey CompetitorsEyenoviaNASDAQ:EYENNkartaNASDAQ:NKTXKamadaNASDAQ:KMDAXOMANASDAQ:XOMAMacroGenicsNASDAQ:MGNXView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 283,193 shares on 7/18/2024Ownership: 0.379%Ngai Hang Victor ChongBought 23,500 shares on 6/24/2024Total: $24,910.00 ($1.06/share)Benjamin R YerxaBought 7,813 shares on 5/15/2024Total: $10,235.03 ($1.31/share)Vanguard Group Inc.Bought 314,480 shares on 5/10/2024Ownership: 3.333%SG Americas Securities LLCBought 32,270 shares on 5/7/2024Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions CLSD Stock Analysis - Frequently Asked Questions How have CLSD shares performed this year? Clearside Biomedical's stock was trading at $1.17 at the beginning of 2024. Since then, CLSD stock has increased by 0.0% and is now trading at $1.17. View the best growth stocks for 2024 here. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The firm earned $0.23 million during the quarter, compared to analyst estimates of $0.98 million. When did Clearside Biomedical IPO? Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. Who are Clearside Biomedical's major shareholders? Top institutional shareholders of Clearside Biomedical include Assenagon Asset Management S.A. (0.38%). Insiders that own company stock include Bradford T Whitmore, George M Lasezkay, Charles A Deignan, Thomas Ciulla, Ngai Hang Victor Chong and Benjamin R Yerxa. View institutional ownership trends. How do I buy shares of Clearside Biomedical? Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), Organigram (OGI) and Zosano Pharma (ZSAN). This page (NASDAQ:CLSD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
